[E-Daily Reporter Park Jung-Soo ] Samchundang Pharmaceutical ( SAM CHUN DANG PHARM CO. LTD(000250)) announced on the 3rd that it has signed a term sheet with global pharmaceutical company Dr. Reddy’s (DRL) regarding two liposome-based drug products.

A term sheet is a document that defines and agrees upon the key terms of a transaction in advance of signing a definitive agreement; the fact that the two companies have signed a term sheet means that an agreement on the broad framework of the transaction has been finalized, signaling that the signing of the definitive agreement is imminent.
The company explained that the signing of this term sheet follows the collaboration on long-acting injectables that SAM CHUN DANG PHARM CO. LTD entered into during the first quarter, and it is significant in that it expands the scope of cooperation between the two companies into the field of highly complex combination formulations.
Liposome formulation is a highly sophisticated drug delivery system (DDS) that encapsulates drugs within a lipid bilayer to enhance delivery efficiency in the body; it is considered a field with high barriers to entry due to its complex manufacturing processes and stringent quality control requirements.
In particular, SAM CHUN DANG PHARM CO. LTD emphasized that through this collaboration, it plans to supply long-acting injectable and complex formulation technology platforms and products, while DRL will handle commercialization and sales by leveraging its global production infrastructure and commercialization network; the company anticipates synergies resulting from the combination of both companies’ core competencies.
SAM CHUN DANG PHARM CO. LTD is fostering its oral platform (S-PASS), long-acting injectables (LAI), and ophthalmic biosimilars as its next-generation growth engines, while continuing to expand strategic collaborations with global partners. The company explained that this collaboration in the liposome field is also an extension of this strategy to expand global partnerships.
SAM CHUN DANG PHARM CO. LTD official stated, “As the scope of our collaboration has expanded from long-acting injectables to liposomes, we are also exploring potential collaborations on additional pipeline projects,” adding, “We will strive to secure mid- to long-term growth potential through the gradual expansion of our collaboration.”
Meanwhile, SAM CHUN DANG PHARM CO. LTD plans to continue follow-up discussions with DRL with the goal of signing a definitive agreement. Following the signing of the definitive agreement, the company plans to proceed sequentially with technology transfer, production of an exhibit batch for regulatory approval, and global regulatory approval procedures.